{"name":"Valent Technologies, LLC","slug":"valent-technologies-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPU01PdmozZEdTS3d5SDhYVjJ6MlNodV9LaVVud0d1dW5OY1FTWXpyUkNEUnowdjVzM3VhRXpfLWx0cGNRYVdod0JpcmgyOVc0NldiMEFiVno5cmlNQkVjYzh5Z3ZUWWhxcDdOS0REMW5EdTA2b21PRjg0bFAxbV9nVnpqUUNHMG1KR0pTZGtyZWk1azU1LXNSQTYtbU5iYXJxZDFxRTR3b0dXYno3aDRZUWluZXRxcmNLZE5sMHliV0xvbF9IZmp1Uk1yd0lJU2JvMm5mazZWQkxLSG1Ba1Vod281aVNoQkJUYnl5dWRLTTUySF9LTnRBTmxKOWk?oc=5","date":"2025-10-27","type":"pipeline","source":"PR Newswire","summary":"Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight - PR Newswire","headline":"Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQd2pnNl93NVIwN3dSMmpYSGNmQVMxZ2Z2SFRGSi1JN1A0aTFuWFRFRDVsN1VmT2Z1UW1WT0QzUXYwSXptQ3lIRTZ3ZDRJc3NVdnI5ZVFZQ3BSSlRHLWU2Z2RzY1Fwa3RjcGhSdERtMU1IanNqajJVRnJnd0dwMHRaRTU5MG9UR2lPeHJUODd2Nk95OWQ0Smx3bGdIc1ZCMEUtUkxxakVyY2NvU1BfZ3RWQ2xfNFpBcVRfQUVHM1Nvd2dIMWR0cTdVd0p0RHBuN3pzNkFHd3Rrc1ctTWlBVFRxcDFxLUJadUExRzkxNHJjQnZzUl9WSGZzMnBkZXFWQ2FrN0I0eHJNNnM?oc=5","date":"2025-08-14","type":"pipeline","source":"PR Newswire","summary":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight - PR Newswire","headline":"Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQMThTUWdpOUNCTS1yUEJydkxSNHlNMG03STQxVkY2ZTVnV2xxNjR4bDJkdnZEQXoyeTJSbDhKbkFWTFlMR3BheEZvb0pwd2xNZ05TZW1Qcmo0N1Q1a0VheE80WUhZQTlNMnlDZ0JDRks5M1BqblhkZWlBcDhTd0dSNmF6OFBxMk5PTVFweTNFRGFmWG9GTDZtNG1JU3VBbVplbEgweVJNNlpCb1ZVSUczeXEyLXZvQ3ZXUVZZSg?oc=5","date":"2025-05-21","type":"patent","source":"Fierce Pharma","summary":"SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine - Fierce Pharma","headline":"SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNa2lHbXRiS1phR2N4NXd0cGxvZDc2OWZQRTQ1dUQxVXlYYl9wZjVON3ZvZmJEc1JrT3ZpekdfZGRMZ3E5UFBxZDVaT19UT0g2SXNzVUVqRkhrbEM4anBBQUJWWk1vNm9NdlRaZTBZWDBFaW1PQ3NYa0t5c3BmQUozQ0U4NHI3VzJjUlp4NmVFRjlJeW9ZQ3JJVkJJRlp3eFBmYkppbFI4RHNXSDBaeVE3bGxnZXdOOTNSNUsyUmlB?oc=5","date":"2024-09-03","type":"pipeline","source":"Fierce Biotech","summary":"Vaxcyte's 'stunning' 31-valent pneumococcal vaccine win against Pfizer's Prevnar 20 has analysts thinking big - Fierce Biotech","headline":"Vaxcyte's 'stunning' 31-valent pneumococcal vaccine win against Pfizer's Prevnar 20 has analysts thinking big","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-28","type":"pipeline","source":"PR Newswire","summary":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight | Key Companies to Watch - Y-mAbs, Exelixis, Clarity, Eli Lilly, Innervate Radio","headline":"Neuroblastoma Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032), Examines DelveInsight ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}